Journal Article

Column-free methods for the fast and versatile isolation of highly purified, functional and expandable human regulatory T cell populations (LL3-3)

A. I. Kokaji, N. MacDonald, M. Fairhurst and T. Thomas

in International Immunology Meeting Abstracts

Volume 22, issue Suppl_1_Pt_3, pages iii7-iii7
Published in print August 2010 |
Published online August 2010 | e-ISSN: XXXX-XXXX | DOI: http://dx.doi.org/10.1093/intimm/dxq203

More Like This

Show all results sharing these subjects:

  • Immunology
  • Biochemical Immunology

GO

Show Summary Details

Preview

Learn how to rapidly and efficiently obtain the highest purity human regulatory T cells (Tregs) directly from whole blood or PBMC in less time with STEMCELL's new range of products. This seminar will demonstrate how you can get your desired population of Tregs based on expression of CD25, CD127, and/or CD49d, while saving hours on the isolation procedure.

STEMCELL's Complete Kits for the isolation of human Tregs reduce cell isolation time by combining two of STEMCELL's rapid and simple cell separation platforms, RosetteSep® and EasySep®. The isolation of Tregs is now a simple two-step process: pre-enrichment of CD4+, CD4+CD127low or CD4+CD49dCD127low cells by negative selection with RosetteSep®, followed by positive selection of CD25high cells with EasySep®. The entire procedure from whole blood or buffy coat to purified Tregs takes only three hours, unlike other magnetic separation methods that take up to five hours to complete. The column-free kits are easy to use and are gentle on cells, providing highly functional Tregs that are immediately ready for use in downstream assays or expanded in vitro while maintaining their functionality. Depending on the desired Treg population, purities of up to 90% CD4+CD25highFOXP3+ human Tregs can be achieved.

Journal Article.  0 words. 

Subjects: Immunology ; Biochemical Immunology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.